Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering exits manufacturing consent decree

Executive Summary

Schering-Plough's petition to dissolve the manufacturing consent decree it has been operating under since May 2002 is granted by U.S. District Court for New Jersey. The company completed the requisite 212 significant steps and 30 validation actions to comply with current good manufacturing practices at the end of 2005 (1"The Pink Sheet" Jan. 09, 2006, In Brief). FDA did not oppose the company's petition, according to Schering...

You may also be interested in...

Schering back in good graces

Schering-Plough completed all 212 significant steps and 30 validation actions required under its manufacturing consent decree by its deadline of Dec. 31, 2005. The goal was reached on time, as the company had anticipated (1"The Pink Sheet" Nov. 14, 2005, p. 28). The consent decree's obligations and requirements are subject to certification by an external third party and review and approval by FDA...

Endo Brings All Xiaflex Revenue In House With BioSpecifics Acquisition

Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.

US FDA Launches Quality Maturity Pilots That Reward High-Performing OTC, Rx Manufacturers

One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts